An interventional study of Resilient Together-YOD and Health Enhancement Program-YOD in Young Onset Dementia, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Dementia by Massachusetts General Hospital — 6 open to participants now, 7 under way, none of them phase 3. Dementia · Massachusetts General Hospital.
Among the 18 studies in Dementia by Massachusetts General Hospital, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 with no phase, and was the 17th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →6 of the 18 studies in Dementia by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 70+
Massachusetts General Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 55–90 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 60+
Massachusetts General Hospital · Sites in United States
Ages 60+
By country, each count listing its studies:
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 388 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 30 across the 15 interventional studies, 150 across the 3 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
2 of the studies in Dementia by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07940335Massachusetts General HospitalLithium Dosing Study | 2027-06-30 |
| NCT06284213Massachusetts General HospitalBiomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Dementia by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the present investigation is to test the efficacy of a virtual, brief (6 sessions) dyadic (patient and care-partner together) intervention to prevent chronic emotional distress in dyads where one person is diagnosed with Young Onset Dementia (YOD). Through this study, we seek to address the unmet need of preventing chronic emotional distress in YOD dyads through a feasible, acceptable and credible program, and ideally enhance resiliency and improve wellbeing and quality of life in both members of the dyad.
The criteria were revised on the registry on Oct 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient Criteria:
Care-Partner Criteria:
Dyad Criteria: (Both Patient and Care-Partner):
-At least one dyad member reports elevated emotional distress (HADS>7)
Exclusion Criteria:
There will be 6 sessions delivered via live video using Zoom. Content will be primarily skills.
Behavioral: Resilient Together-YOD
There will be 6 sessions delivered via live video using Zoom. Content will be primarily educational.
Behavioral: Health Enhancement Program-YOD
This is a 6 session dyadic (patient and spousal care-partner) intervention that teaches resiliency and interpersonal communication skills early after YOD diagnoses. It aims to decrease heightened symptoms of depression and anxiety among dyads to help them engage in important decisions around long term care-planning and optimize adjustment. The goal is to equip dyads with the necessary skills to cope and engage in meaningful, challenging conversations around care-planning, symptom deterioration, work/family planning to improve well-being in both members of the dyad.
Also known as: Skills-based intervention
This is a 6 session program that will deliver educational information to dyads and will mimic the dose and duration of Resilient Together. The program will not teach any individual and dyadic interpersonal skills, but will contain education on psychological distress and healthy behaviors. Sessions will also be delivered virtually.
Also known as: Educational program
Change in Emotional Distress
Hospital Depression and Anxiety Scale total score (HADS); 0-21 for each subscale (anxiety and depression), higher scores indicate greater anxiety or depression
Time frame: 0 weeks, 6 weeks, 12 weeks
Change in Resiliency Factors (Mindfulness)
Cognitive and Affective Mindfulness Scale (CAMS); 12-48, higher scores indicate greater perceived mindfulness
Time frame: 0 weeks, 6 weeks, 12 weeks
Change in Resiliency Factors (Individual Coping)
Measure of Current Status Part A (MOCS-A) Assertiveness and Coping Confidence subscales; Subscale scores: 0-4; higher scores indicate greater perceived ability to cope
Time frame: 0 week, 6 weeks, 12 weeks
Change in Resiliency Factors (Mindfulness Utilization)
Applied Mindfulness Scale (AMPS); 0-60, higher scores indicate greater use of mindfulness practices.
Time frame: 0 weeks, 6 weeks, 12 weeks
Changes in Interpersonal Factors (Dyad Coping)
Dyadic Coping Inventory (DCI); 37-185, higher scores indicate greater perceived coping in the context of a relationship
Time frame: 0 weeks, 6 weeks, 12 weeks
Changes in Resiliency Factors (Perceived Social Support)
Multidimensional Scale of Perceived Social Support (MSPSS); 12-84, higher scores indicate greater perceived social support from family, friends, and significant others
Time frame: 0 weeks, 6 weeks, 12 weeks
Changes in Resiliency Factors (Values-based Living)
Valuing Questionnaire (VQ); Progress and Obstruction Subscale Scores: 0-30, higher scores indicate living in greater accordance with one's values
Time frame: 0 weeks, 6 weeks, 12 weeks
Global Impressions of Change
Modified Global Impressions of Chance (MGIC); 1-7, higher scores indicate greater perceived change in outcomes
Time frame: 6 weeks, 12 weeks
Cognition
Montreal Cognitive Assessment (MoCA); 0-30, lower scores indicate greater cognitive dysfunction
Time frame: 0 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2030, 53 months after the start.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 53 months is above that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →